financetom
Business
financetom
/
Business
/
Why Canoo (GOEV) Stock Is Skyrocketing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Canoo (GOEV) Stock Is Skyrocketing
Mar 18, 2024 7:27 AM

Canoo Inc ( GOEV ) shares are trading higher by 56% to $3.03 during Monday’s session after the U.S. Department of Commerce has approved its Oklahoma City facility as a Foreign Trade Zone.

The company says FTZ designation enables Canoo ( GOEV ) to eliminate customs duties on vehicles sold internationally and defer duties on imported parts used in domestic sales. The company sources over 90% of its parts from the U.S. and allied nations, with 70% from North America. This designation is expected to reduce vehicle costs by up to 5% for international sales and improve working capital for domestic sales by deferring customs duties until the vehicle is delivered to customers.

Tony Aquila, Canoo’s Investor, Executive Chairman and CEO, expressed gratitude to stakeholders for achieving this milestone, emphasizing the economic growth, job creation, and long-term financial benefits for Canoo ( GOEV ). The company plans to expand its manufacturing site in Oklahoma, aiming to bring more supply partners closer to the facility. Canoo’s manufacturing strategy focuses on owning the supply chain, distinguishing it from competitors who outsource these operations.

Canoo ( GOEV ) is seeking approval for its remaining manufacturing facilities in Oklahoma, with plans to establish one of the largest FTZs in the state. This expansion is expected to generate high-paying direct and indirect jobs, contributing to the growth of the advanced manufacturing sector in America’s heartland.

See Also: Apple Is Sending Alphabet Stock Higher Monday: What’s Going On?

Is GOEV A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Canoo ( GOEV )‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Canoo ( GOEV )) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 25.59%, you'll need to buy a share of Dividend 15 Split Corp by the Mar. 27, 2024. Once done, you can expect to receive a nominal payout of $0.1 on Apr. 10, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Canoo ( GOEV ) will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, GOEV has a 52-week high of $19.50 and a 52-week low of $1.22.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Starboard seeks probe after former Pfizer execs pull support for its campaign
Starboard seeks probe after former Pfizer execs pull support for its campaign
Oct 10, 2024
(Reuters) - Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday. Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, who were reportedly helping the activist investor in its plan to push...
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Oct 10, 2024
09:25 AM EDT, 10/10/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Thursday that volixibat has received breakthrough therapy designation from the US Food and Drug Administration as a potential treatment for cholestatic pruritus related to primary biliary cholangitis. The company said the designation is based on the interim analysis of a phase 2b study that demonstrated statistically significant...
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Oct 10, 2024
Indivior PLC ( INDV ) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior ( INDV ) trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion –...
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Oct 10, 2024
09:24 AM EDT, 10/10/2024 (MT Newswires) -- Delta Air Lines ( DAL ) issued a weak fourth-quarter earnings outlook amid expectations for subdued travel demand around the US Presidential elections in November, as the air carrier's bottom line fell short of market estimates in the prior three-month period while revenue beat Wall Street forecasts. The airline anticipates adjusted earnings to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved